Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 2/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | BCR | P11274 | 1/20 | 0.47 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GCGR | P47871 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15588476 | 0.89 | APP (0.51) | CYP2C19APPNFE2L2NPC1RAB9A | |
| SCHEMBL30979884 | 0.89 | APP (0.51) | CYP2C19APPNFE2L2NPC1RAB9A | |
| SCHEMBL27781767 | 0.88 | CYP2C19 (0.58) | CYP2C19APPABL1ABCB1BCR | |
| SCHEMBL30979865 | 0.88 | APP (0.46) | CYP2C19APPSYKNFE2L2NPC1 | |
| SCHEMBL16184211 | 0.86 | CYP2C19 (0.56) | CYP2C19APPNPC1RAB9AABL1 | |
| SCHEMBL6004654 | 0.86 | GSTP1 (0.57) | CYP2C19APPNFE2L2NPC1RAB9A | |
| SCHEMBL30979851 | 0.85 | NFE2L2 (0.51) | CYP2C19APPSYKNFE2L2NPC1 | |
| SCHEMBL11691477 | 0.83 | SYK (0.48) | CYP2C19SYKNFE2L2NPC1RAB9A | |
| SCHEMBL12508085 | 0.83 | CYP2C19 (0.54) | CYP2C19APPSYKNPC1RAB9A | |
| SCHEMBL6161635 | 0.82 | STAT3 (0.48) | CYP2C19APPSYKNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | claimed |
| EP-4328222-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-02-28 | — | — | EP | claimed |
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | disclosed |
| EP-4328222-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022225238-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 보로노이 주식회사 | 2022-10-27 | — | — | WO | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-0494419-B1 | Process for the preparation of 5-(2,4-difluorophenyl)-salicylic acid | ZAMBON SPA (IT) | 1995-12-06 | — | — | EP | disclosed |
| US-5412143-A | Process for the preparation of 5-(2,4-difluorophenyl)-salicylic acid | ZAMBON GROUP S.P.A. (IT) | 1995-05-02 | — | — | US | disclosed |
| US-5312975-A | Process for the preparation of 5-(2,4-difluorophenyl)-salicylic acid | ZAMBON GROUP S.P.A. (IT) | 1994-05-17 | — | — | US | disclosed |
| EP-0494419-A2 | Process for the preparation of 5-(2,4-difluorophenyl)-salicylic acid | ZAMBON GROUP S.p.A. (IT) | 1992-07-15 | — | — | EP | disclosed |
| US-4044049-A | Phenyl benzoic acid compounds | MERCK & CO., INC. (US) | 1977-08-23 | — | — | US | disclosed |
| US-3992459-A | BIARYL COUPLING BY DIAZOTIZATION | MERCK & CO., INC. (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | CYP2C19 712/4885APP 3746/4885SYK 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.